Christopher F. Barnett, M.D., M.P.H., discusses the risk for developing pulmonary arterial hypertension (PAH) in people with human immunodeficiency virus (HIV), how it is diagnosed and current treatment options. PHA thanks Janssen Pharmaceuticals for its Diamond sponsorship of the Associated Disease Outreach & Engagement Program, which provides support to this PHA Live event.

Vineet Agrawal, M.D., Ph.D., discusses left heart disease and the various ways it can lead to pulmonary hypertension (PH), highlights the importance of accurate diagnosis and shares treatment options. PHA thanks Janssen Pharmaceuticals for its Diamond sponsorship of the Associated Disease Outreach & Engagement Program, which provides support to this PHA Live event. 

Ivan Robbins, M.D., discusses CTEPH, highlights the importance of diagnosis and shares treatment options for individuals with pulmonary hypertension (PH) related to chronic thromboembolic disease. PHA thanks Janssen Pharmaceuticals for its Diamond sponsorship and Bayer HealthCare for its Platinum sponsorship of the PHA Connects Fund, which provides support to this PHA Live event.

John T. Berger III, M.D., discusses congenital heart disease (CHD) and reviews types of heart and blood vessel abnormalities that can develop before a person is born that could lead to pulmonary hypertension (PH). PHA thanks Janssen Pharmaceuticals for its Diamond Sponsorship of the Associated Disease Outreach & Engagement Program, which provides support to this PHA Live event.

Dan Grinnan, M.D., speaks with one of his pulmonary hypertension (PH) patients, Shirl Rhodes, about her enrollment in the PHA Registry (PHAR), a registry of patients with pulmonary arterial hypertension (PAH), pediatric PH due to developmental lung disease and chronic thromboembolic pulmonary hypertension (CTEPH). Learn what it is like to participate in the PHAR and how PHAR supports PH research. PHA thanks Bayer for its Platinum Sponsorship and Janssen Pharmaceuticals, Inc. for its Diamond Sponsorship of the PHA Connects fund, which provides support to this PHA Live event.

Scientists and clinicians present findings from the 2018 PHA Research Room, the Pulmonary Hypertension Association (PHA)’s research project providing pulmonary hypertension (PH) patients the opportunity to participate in clinical research studies. Learn about pulmonary arterial hypertension (PAH) biomarkers, patient survey results from support group therapy, an outcomes risk assessment tool for PH patients and barriers to exercise therapy in PH. PHA thanks Bayer for its Platinum Sponsorship and Janssen Pharmaceuticals, Inc. for its Diamond Sponsorship of the PHA Connects fund, which provides support to this PHA Live event.

Dr. Wendy Chung discusses the basics of genetics, hereditary pulmonary arterial hypertension (HPAH) and the genetic causes of pulmonary arterial hypertension (PAH). She explains commonly used genetic tests for pulmonary hypertension (PH) in the United States and addresses what happens during a genetic counseling session.

Members of PHA’s COVID-19 Task Force discuss COVID-19 vaccines, virus variants, current safety recommendations and more. PHA thanks Bayer for its Platinum Sponsorship and Janssen Pharmaceuticals, Inc. for its Diamond Sponsorship of the PHA Connects fund, which provides support to this PHA Live event.

Namita Sood, M.D., F.C.C.P., discusses the risk of pulmonary hypertension (PH) in individuals with Sjögren's, a rare autoimmune disorder. Learn about PH symptoms, diagnosis and treatment options.

Dr. Eric Austin discusses how pulmonary hypertension (PH) affects children and answers common questions about heritable pulmonary atrial hypertension (PAH). The event will help parents to understand how pediatric PH is treated. PHA thanks Janssen Pharmaceuticals, Inc. for its diamond sponsorship of the PHA Connects fund, which provides support to this PHA Live event.